Lv1
30 积分 2022-12-27 加入
Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?
25天前
已完结
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients
1个月前
已完结
Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study
1个月前
已完结
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?
2个月前
已完结
Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis
3个月前
已完结
The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer
5个月前
已完结
Immune checkpoint inhibitors in endometrial cancer
5个月前
已完结
Immune checkpoint inhibitors for recurrent endometrial cancer
5个月前
已完结
Immunotherapy in endometrial cancer
6个月前
已完结
Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report
9个月前
已完结
皖公网安备34019202002308
